Epista appoints Per Johansson as new CEO to lead global growth

Horsholm, Denmark – Epista Life Science today announced the planned transition of their CEO, ushering in a new chapter of global growth.

After more than 16 years at the helm, founder Klavs Esbjerg will hand over the CEO role at the end of 2025. Per Johansson, former CEO of KMD Group, will take over the position, while Klavs will remain a significant shareholder and continue as an active member of the Board of Directors, serving as a strategic advisory capacity to help guide Epista’s long-term vision and value.

Founded by Klavs in 2009, Epista has grown from a small Danish consultancy into a trusted global partner for life science companies, with more than 200 employees across Europe and the US.

Under his leadership, Epista has built an excellent reputation on the fundamentals of a strong differentiating culture with a value set of ‘Trustworthy Conduct’, ‘Lasting Relationships’, ‘Recognized Expertise’, and ‘Measurable Results’.  

These values have become a defining pillar of the company’s success in defining and delivering excellence to life science companies globally and that that remain foundational to Epista’s culture and success moving forward.

Reflecting on the transition, Klavs says:

“I am extremely proud of the journey Epista has been on so far, which is truly due to a fantastic team. Our people-first mindset and strong values have been essential in building a brand that clients trust and feel safe working with. With a market full of opportunity, I look forward to supporting Epista and Per in the continued success of the company.”

Per Johansson brings extensive experience in international scaling, strategic leadership, and software development. At KMD, he led a significant transformation and growth strategy. He now joins Epista to drive the company’s next global chapter.

“Life Sciences is one of the most exciting global growth markets, driven by rapid technological development and increasing demands for security, compliance, and efficiency. Epista is already a trusted partner and holds a strong position in this space. I look forward to building on the foundation created by Klavs and the team,” says Per Johansson.

As Epista enters a new phase, Klavs will remain closely involved in shaping the company's future direction. His continued presence ensures that his in-depth knowledge and the values and culture established will remain central as Per leads the organization into its next stage of growth.  

This transition reflects Epista’s growth as a mature, global business with continued ambition. With Klavs Esbjerg staying actively involved and Per Johansson bringing a forward-looking perspective, Epista is well positioned to enter its next phase of growth while staying true to the principles that have always set it apart.

‍

Link for Danish version

______________________________

For more information please contact:

General contact:
Flemming Kjøller
Senior Vice President
flk@epista.com
+45 2151 0922

Media inquiries:
Mads Torry Lindeneg
Director, Communication & Marketing
mtl@epista.com
+45 3075 1845

‍

About Epista

Epista Life Science is a consulting firm that specializes in helping life sciences companies achieve compliance, process optimization, and regulatory alignment. With over 200 experts across five countries, Epista supports clients in navigating complex regulatory landscapes, ensuring efficiency and product quality. Since its founding in 2009, Epista has focused on enhancing global health through rigorous standards and collaborative innovation. Learn more at Epista Life Science.

‍

‍

‍